Fresolimumab Treatment Decreases Biomarkers and Improves Clinical Symptoms in Systemic Sclerosis Patients by Rice, Lisa M et al.
Dartmouth College
Dartmouth Digital Commons
Open Dartmouth: Faculty Open Access Articles
6-22-2015
Fresolimumab Treatment Decreases Biomarkers
and Improves Clinical Symptoms in Systemic
Sclerosis Patients
Lisa M. Rice
Boston University School of Medicine
Cristina M. Padilla
Boston University School of Medicine
Sarah R. McLaughlin
Boston University School of Medicine
Allison Mathes
Boston University School of Medicine
Jessica Ziemek
Boston University School of Medicine
See next page for additional authors
Follow this and additional works at: https://digitalcommons.dartmouth.edu/facoa
Part of the Medicine and Health Sciences Commons
This Article is brought to you for free and open access by Dartmouth Digital Commons. It has been accepted for inclusion in Open Dartmouth: Faculty
Open Access Articles by an authorized administrator of Dartmouth Digital Commons. For more information, please contact
dartmouthdigitalcommons@groups.dartmouth.edu.
Recommended Citation
Rice, Lisa M.; Padilla, Cristina M.; McLaughlin, Sarah R.; Mathes, Allison; Ziemek, Jessica; Goummih, Salma; Nakerakanti,
Sashidhar; York, Michael; Farina, Giuseppina; Whitfield, Michael L.; Spiera, Robert F.; Christmann, Romy B.; Gordon, Jessica K.;
Weinberg, Janice; and Lafyatis, Robert, "Fresolimumab Treatment Decreases Biomarkers and Improves Clinical Symptoms in
Systemic Sclerosis Patients" (2015). Open Dartmouth: Faculty Open Access Articles. 3621.
https://digitalcommons.dartmouth.edu/facoa/3621
Authors
Lisa M. Rice, Cristina M. Padilla, Sarah R. McLaughlin, Allison Mathes, Jessica Ziemek, Salma Goummih,
Sashidhar Nakerakanti, Michael York, Giuseppina Farina, Michael L. Whitfield, Robert F. Spiera, Romy B.
Christmann, Jessica K. Gordon, Janice Weinberg, and Robert Lafyatis
This article is available at Dartmouth Digital Commons: https://digitalcommons.dartmouth.edu/facoa/3621
The Journal of Clinical Investigation   C l i n i C a l  M e d i C i n e
2 7 9 5jci.org   Volume 125   Number 7   July 2015
BACKGROUND. TGF-β has potent profibrotic activity in vitro and has long been implicated in systemic sclerosis (SSc), as 
expression of TGF-β–regulated genes is increased in the skin and lungs of patients with SSc. Therefore, inhibition of TGF-β 
may benefit these patients.
METHODS. Patients with early, diffuse cutaneous SSc were enrolled in an open-label trial of fresolimumab, a high-affinity 
neutralizing antibody that targets all 3 TGF-β isoforms. Seven patients received two 1 mg/kg doses of fresolimumab, and eight 
patients received one 5 mg/kg dose of fresolimumab. Serial mid-forearm skin biopsies, performed before and after treatment, 
were analyzed for expression of the TGF-β–regulated biomarker genes thrombospondin-1 (THBS1) and cartilage oligomeric 
protein (COMP) and stained for myofibroblasts. Clinical skin disease was assessed using the modified Rodnan skin score (MRSS).
RESULTS. In patient skin, THBS1 expression rapidly declined after fresolimumab treatment in both groups (P = 0.0313 
at 7 weeks and P = 0.0156 at 3 weeks), and skin expression of COMP exhibited a strong downward trend in both groups. 
Clinical skin disease dramatically and rapidly decreased (P < 0.001 at all time points). Expression levels of other TGF-β–
regulated genes, including SERPINE1 and CTGF, declined (P = 0.049 and P = 0.012, respectively), and a 2-gene, longitudinal 
pharmacodynamic biomarker of SSc skin disease decreased after fresolimumab treatment (P = 0.0067). Dermal myofibroblast 
infiltration also declined in patient skin after fresolimumab (P < 0.05). Baseline levels of THBS1 were predictive of reduced 
THBS1 expression and improved MRSS after fresolimumab treatment.
CONCLUSION. The rapid inhibition of TGF-β–regulated gene expression in response to fresolimumab strongly implicates 
TGF-β in the pathogenesis of fibrosis in SSc. Parallel improvement in the MRSS indicates that fresolimumab rapidly reverses 
markers of skin fibrosis.
TRIAL REGISTRATION. Clinicaltrials.gov NCT01284322.
FUNDING. This study was supported by the Boston University Clinical and Translational Science Institute, the NIH’s 
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fibrosis after myocardial infarctions and associated with hyper-
tension, and pulmonary fibrosis, either idiopathic or associated 
with a variety of other diseases or environmental exposures (9). 
Although skin disease in SSc does not cause death, extensive skin 
disease is associated with considerable morbidity and severity of 
internal organ disease as well as disease-associated mortality (10). 
In addition, skin fibrosis shares pathogenic features with fibrotic 
disease at other sites in patients with SSc, suggesting that agents 
successfully treating skin might show efficacy for other involved 
organs (11). As skin can be easily biopsied, it provides a window 
into understanding pathogenesis and also a methodology for 
assessing response of a target organ.
Several factors have slowed development of therapeutics tar-
geting fibrosis in SSc. The variable trajectory of disease progression 
in different organs in patients with SSc has led to particular chal-
lenges in identifying efficacy in early-phase clinical trials; this has 
included slow rates of progression of interstitial lung disease (12) 
and spontaneous improvement of skin disease (13). In addition, 
the relatively slow rate of change in skin disease, as assessed by the 
main clinical outcome, the modified Rodnan skin score (MRSS), 
and the relative insensitivity of the MRSS to change has led to the 
notion that changes in the MRSS require long periods of observa-
tion to detect. The clinical heterogeneity of the disease and years-
long progression have made it difficult to demonstrate efficacy in 
large, placebo-controlled, 12- to 24-month clinical trials in Ssc, 
even in the early phase of clinical development (14), presenting a 
significant obstacle for discovering effective therapies for SSc.
Biomarkers that correlate with the MRSS might act as surro-
gate outcome measures for the degree of skin disease in patients 
with SSc and thus provide an approach for more quickly detecting 
potential drug efficacy in early-phase SSc clinical trials. Biomark-
ers can be measured objectively and might be expected to change 
more quickly than clinical outcome measures such as the MRSS. 
We previously described a 4-gene, pharmacodynamic biomarker 
of SSc skin disease, based on gene expression in a mid-forearm 
skin biopsy (15). Two of the four genes making up the biomarker, 
thrombospondin-1 (THBS1) and cartilage oligomeric protein 
(COMP), are highly regulated by TGF-β. Thus, to test the impor-
tance of TGF-β in SSc skin fibrosis as well as to test a biomarker- 
based approach to early-phase clinical trial design, we treated 
patients with early, diffuse SSc with fresolimumab, a first-in-class 
human IgG4 κ monoclonal antibody capable of neutralizing all 
mammalian isoforms of TGF-β. The predefined primary efficacy 
outcome for this trial was change in COMP and THBS1 mRNA 
expression in skin after treatment compared with that at baseline.
Results
Patients. Patients were mostly female, with a median age of 51 
years and median MRSS of 24 (Table 1). Only one patient showed 
signs of interstitial lung disease, with a median forced vital 
capacity of 90% predicted. Four patients (27%) had anti-Scl70 
autoantibodies, and eight patients (53%) had anti–RNA poly-
merase (anti-Pol3) III autoantibodies. Anti-Pol3 autoantibodies 
are typically seen in only about 11% of all patients with SSc (16) 
but are much more common in patients with diffuse cutaneous 
disease (17). Since anti-Pol3 autoantibodies are associated with 
more severe skin disease and less severe interstitial lung disease 
Introduction
Soon after its discovery as a transforming growth factor, TGF-β 
was recognized to have potent profibrotic activity (1, 2). TGF-β pro-
motes collagen synthesis, secretion, processing, and cross-linking 
(3) as well as secretion of other matrix molecules, such as fibronec-
tin and thrombospondin (4). All 3 TGF-β isotypes (TGF-β1, TGF-β2, 
and TGF-β3) interact with the same receptor complex and have 
wide-ranging, context-specific effects on cell proliferation and dif-
ferentiation, embryological processes, and the immune system (5).
Fibrosis in patients with systemic sclerosis (SSc) affects the 
skin in addition to internal organs: lungs, heart, and gastrointesti-
nal tract (6). It represents a major unmet therapeutic challenge, as 
treatment for SSc fibrotic disease is currently limited to cyclophos-
phamide, which has modest effects (7); immunoablation and stem 
cell transplant offer a more dramatic benefit, which is associated 
with significant treatment-associated morbidity and mortality (8). 
Further, fibrosis is an end-stage process in many diseases, includ-
ing many common diseases, such as liver cirrhosis complicating 
viral or drug-induced hepatitis, renal fibrosis as the pathological 
feature leading to many forms of end-stage renal disease, cardiac 
Table 1. Baseline demographic and clinical characteristics of 
study patients (n = 15)
Characteristic Value
Age, yr
 Mean (SD) 51.73 (10.72)
 Median 51
Sex F (M) 11 (4)
MRSS
 Mean (SD) 26.9 (8.26)
 Median 24
Presence of digital ulcers (no. [%]) 9 (60)
FVC
 Mean (SD) 94 (17.34)
 Median 90
DLCO
 Mean (SD) 82.13 (13.77)
 Median 82
Presence of ILD on high-resolution chest CT (no. [%]) 1 (6.67)
Disease duration 
 Mean (mo. from first non-Raynaud’s disease manifestation [SD]) 19.21 (19.73)
 Median (mo. from first non-Raynaud’s disease manifestation) 15.5
Raynaud’s disease manifestation
 Mean (mo. before trial entry [SD]) 37.86 (46.62)
 Median (mo. before trial entry) 19.5
Diagnosis of SSc
 Mean (mo. before trial entry [SD]) 8(6.23)
 Median (mo. before trial entry) 5
Autoantibodies 
 Antinuclear antibody (no. [%]) 14 (93)
 Anti-Scl70 antibody (no. [%]) 4 (27)
 Anti-Pol3 (no. [%]) 8 (53)
 Anticentromere antibody (no. [%]) 1 (7)
 Antifibrillarin (no. [%]) 7 (47)
FVC, forced vital capacity; DLCO, diffusion capacity; ILD, interstitial lung 
disease.
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Figure 3B and Supplemental Figure 1B) and COMP (66.7% of 
baseline; P = 0.0781, Figure 3D and Supplemental Figure 1D), 
which reached a nadir at week 3. Decreases in gene expression 
seen at weeks 3 or 4 and week 7 were lost at week 24 (Figure 3, 
A–D), a time when circulating fresolimumab was mostly metab-
olized (Figure 2B). However, in the first dosing group, the loss 
of significant change at week 24 might reflect the fewer biopsies 
available for analysis.
Changes in gene expression in study patients generally cor-
related with changes in MRSS (compare Supplemental Figure 1, 
A and C with Supplemental Figure 1E and Supplemental Figure 1, 
B and D with Supplemental Figure 1F). Examining the correlation 
between the MRSS and biomarkers in all biopsies revealed a high 
correlation for THBS1 (r = 0.63) and COMP (r = 0.62) (data not 
shown), similar to correlations we reported previously between 
the MRSS and gene expression (15). Baseline THBS1 and COMP 
gene expression was strikingly higher in both SSc patient cohorts 
than in healthy control skin, as we have reported previously (Fig-
ure 3, A–D, and ref. 15). Median baseline values were higher in the 
first cohort (THBS1 = 11.63, COMP = 36.84) compared with those 
in the second cohort (THBS1 = 5.97, COMP = 16.20; Figure 3, A–D), 
as were median baseline MRSS values (25 and 22.5, respectively).
Summary statistics using all available data for patients entered 
into both treatment groups showed that THBS1 and COMP expres-
sion declined rapidly after fresolimumab treatment (Table 2). 
Gene expression results from skin biopsies following treatment in 
the first group at 3 weeks and in the second group at 4 weeks were 
combined for these analyses. Median THBS1 levels at week 3 or 4 
were 77% of baseline, reaching a nadir at week 7 of 61% of baseline 
THBS1 expression. Median COMP levels at week 3 or 4 and week 
7 were 60% and 75% of baseline COMP expression , respectively. 
(17), our entry criteria, which included only patients with diffuse 
cutaneous disease and excluded patients with significant lung 
disease, likely enriched for patients with this autoantibody spec-
ificity. Two groups of patients were treated with fresolimumab: 
the first group (group 1, n = 7) was treated with 2 doses of 1 mg/
kg fresolimumab 4 weeks apart, and the second group (group 2, 
n = 8) was treated with 1 dose of 5 mg/kg fresolimumab (Figure 1 
and Figure 2A). Skin biopsies were performed at baseline (the day 
of first infusion) and at 3 weeks (group 1) or 4 weeks (group 2), 
7 weeks, and 24 weeks after the baseline biopsy (Figure 2A).
Skin biomarker gene expression of THBS1 shows a rapid decline 
after fresolimumab treatment. The 2 groups of patients showed 
dramatically different serum levels of fresolimumab, with group 2 
reaching approximately 5 times higher serum levels 3 weeks after 
treatment than group 1 (Figure 2B). Even after the first group of 
patients received a second 1 mg/kg dose of study medication, 
the relative levels of circulating fresolimumab were nearly twice 
as high in the second group (receiving a single 5 mg/kg dose) at 
7 weeks and subsequent time points due to the circulating half-life 
of approximately 22 days.
Both treatment groups separately showed rapid declines in 
THBS1 and COMP gene expression, the primary efficacy out-
come measure (Figure 3, A–D, and Supplemental Table 1A; sup-
plemental material available online with this article; doi:10.1172/
JCI77958DS1). Patients in the first dosing group showed a signifi-
cant decline in median THBS1 expression (67.2% of baseline) at 7 
weeks compared with that at baseline (P = 0.0313, Figure 3A and 
Supplemental Figure 1A), and a trend toward decreased COMP 
expression (77.1% of baseline) (P = 0.218, Figure 3C and Supple-
mental Figure 1C). Patients in the second dosing group showed 
a more rapid decrease in THBS1 (70.0% of baseline; P = 0.0156, 
Figure 1. CONSORT flow dia-
gram. Schematic of patient 
screening, enrollment, and 
completion of the trial in the 
two study groups. 
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Some studies have shown that longer disease duration is asso-
ciated with spontaneous improvement in skin disease in patients 
with SSc (18). However, in patients in this early disease cohort, we 
found no relationship between the baseline disease duration and 
the subsequent change in MRSS (Supplemental Figure 4).
Skin disease shows rapid improvement after fresolimumab 
treatment. The primary clinical outcome in this trial, the MRSS, 
declined rapidly in most patients, generally within several weeks 
of the infusion (Table 2). Examining the change in MRSS in each 
study group separately showed similar seeming response kinetics, 
with both groups showing rapid decreases in mean MRSS as soon 
as the first follow-up study visit, and then increasing skin scores by 
the week 24 study visit, apparently representing recurrent disease 
(Figure 3, E and F, and Supplemental Table 1B).
The median change in MRSS, using all available data across 
both dose groups, was most striking at weeks 11 and 17, –6 
(P = 0.0005) and –9.5 (P = 0.0024), respectively (Table 2). Many 
patients then showed recurrent disease, i.e., an increase in the 
MRSS at a later point in the trial. The repeated-measures model 
reinforced the analysis of all available data (Table 3), with a nadir 
in the predicted change of –8 at week 11 (P = 0.0002). There was 
no statistically significant dose by time interaction in the repeated- 
measures model, indicating that the patterns of change over time 
in MRSS were somewhat similar for the 2 dose groups (P = 0.4168).
Decreased expression of a coregulated cluster of TGF-β–regu-
lated genes and macrophage-associated genes after fresolimumab 
treatment. To further understand the genes regulated by fresoli-
mumab in the study patients, biopsies were analyzed by microar-
ray. Clustering of these genes revealed a readily recognizable 
cluster of TGF-β–regulated genes that included both of the genes 
predefined as the primary outcome measures: THBS1 and COMP 
(Figure 4). All of the genes in this cluster were found to correlate 
highly with the MRSS (Figure 4). Genes clustering with the pri-
mary outcome measures included several genes regulated by 
TGF-β: connective tissue growth factor (CTGF, also known as 
CCN2) (19), cadherin 11 (CAD11) (20), NADPH oxidase 4 (NOX4) 
(21), collagen X α 1 (COL10A1) (22), and collagen XI, α 1 (23). We 
quantified expression of several TGF-β and collagen genes by 
RT-PCR. CTGF, SERPINE1, and COL10A1 expression levels all 
Examining gene expression of evaluable, paired biopsies from both 
treatment groups, median THBS1 expression decreased by –1.5 
(P = 0.0135) and –1 (P = 0.004) at week 3 or 4 and week 7, respec-
tively (from baseline median of 8), and median COMP expression 
decreased by –7.9 (P = 0.058) and –4.3 (P = 0.153) at week 3 or 4 and 
week 7, respectively (from baseline median of 22.6).
To verify the results using an analytic method robust in 
accounting for “missing-at-random” data, we used a repeated- 
measures model to take advantage of the multiple measure-
ments per subject. Controlling for dose group, the predicted mean 
changes from baseline (β coefficients) closely paralleled the results 
obtained using all available data (Table 3). Changes in THBS1 
and COMP expression were largest at week 7, with predicted 
decreases of –3.4 (P = 0.018) and –3.6 (P = 0.135), respectively. The 
dose by time interaction terms were significant for both THBS1 
(P = 0.0012) and COMP (P = 0.0492), indicating that the patterns 
of change over time differed by dose group.
To better understand the relationship between the skin score 
at the biopsy site and gene expression, we compared gene expres-
sion of THBS1 and COMP to the local forearm skin score, the 0–3 
score performed on the same day as the biopsy. The local skin 
score correlated highly with the MRSS and also with expression of 
both THBS1 and COMP (Supplemental Figure 2). We also exam-
ined autoantibody levels after treatment (week 11) compared with 
those at baseline (Supplemental Figure 3). Anti-Scl70 autoanti-
body levels fell modestly in all patients (4 of 4), but our patient 
group’s size was not sufficient to indicate a statistically meaning-
ful result. Anti-Pol3 levels showed no consistent change, rising in 
some patients and falling in others. We also examined the effects of 
autoantibody status on the clinical response. The change in MRSS 
in anti-Pol3–negative or anti-Scl70–negative patients (median 
change = –12) was higher than that in anti-Scl70–positive (median 
change = –5) or anti-Pol3–positive patients (median change = –2), 
but these groups were too small to make a meaningful statistical 
comparison. The change in MRSS was different when comparing 
anti-Pol3–positive patients (median change in MRSS = –2) to anti-
Pol3–negative patients (grouping anti-Scl70–positive patients with 
patients negative for both anti-Scl70 and anti-Pol3; mean change 
in MRSS = –6, P = 0.014) at week 7 but not at week 3 or 4 (P = 0.33).
Figure 2. Study design and pharmacokinetics of fresolimumab 
in two dosing groups. (A) Trial protocol for each group shows 
dosing levels and frequency and timing of skin biopsies. Red 
arrows indicate skin biopsies. (B) Fresolimumab levels measured 
in sera at 3, 7, 11, 17, and 24 weeks in group 1, which received 2 
doses of 1 mg/kg at weeks 0 and 4 (blue diamonds), and group 2, 
which received a single dose of 5 mg/kg fresolimumab at week 0 
(red squares). Error bars indicate SD.
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trial included very similar patients with early, diffuse SSc (Sup-
plemental Table 2), but skin biopsies were analyzed at baseline, 
6 months, and 12 months. This longer time interval between biop-
sies would be expected to show more dramatic changes in the 
2GSSc skin biomarker than seen in samples from fresolimumab- 
treated patients, due to the natural history of the disease. In contrast 
to samples from fresolimumab-treated patients, nilotinib-treated 
patients showed no significant change in 2GSSc skin biomarker at 
6 and 12 months compared with that at baseline (Figure 6B).
Inhibition of myofibroblasts and plasminogen activator protein-1 
in fresolimumab-treated patients. TGF-β stimulates fibroblast dif-
ferentiation into myofibroblasts, the cell type consistently impli-
cated in fibrosis in many diseases (25). Myofibroblasts are sensi-
tive markers of SSc skin disease, and the intensity of myofibroblast 
infiltration correlates highly with the severity of skin disease, as 
assessed by the MRSS (26). In several patients, fresolimumab 
treatment was associated with a particularly rapid, dramatic 
declined after fresolimumab treatment compared with those at 
baseline (Figure 5, A–C).
We also examined the microarray expression of inflammatory 
genes after fresolimumab treatment. CD14, CD163, and MS4A4A, 
all genes expressed mainly in monocytes/macrophages, clustered 
together (data not shown). Expression of CD163, tested by Nano-
String, trended lower after fresolimumab treatment (Figure 5D).
Decreased expression of a SSc skin pharmacodynamic biomarker 
after fresolimumab treatment. We tested the effect of treatment 
with fresolimumab on a recently developed, multianalyte, longi-
tudinal pharmacodynamic biomarker (2GSSc skin biomarker; ref. 
24). This biomarker is composed of weighted values for THBS1 
and MS4A4A mRNA expression assessed by NanoString. The 
2GSSc skin biomarker showed reduced expression at both week 
3 or 4 and week 7 after fresolimumab treatment compared with 
baseline expression levels (Figure 6A). We compared the 2GSSc 
biomarker in samples from a clinical trial of nilotinib in SSc. This 
Figure 3. Changes in biomarker gene 
expression and MRSS by study group.  
(A and B) THBS1 and (C and D) COMP 
gene expression and (E and F) MRSS from 
study patients in (A, C, and E) group 1  
(n = 7), which received 2 doses of 1 mg/kg  
fresolimumab, and (B, D, and F) group 2 
(n = 8), which received 1 dose of 5 mg/kg 
fresolimumab. Dot plots show median 
(horizontal bars) and statistical signifi-
cance of THBS1 and COMP gene expres-
sion (Wilcoxon signed-rank test, using 
available data). Box plots show median 
(horizontal line), interquartile (box), 
and 95% confidence limits (whiskers) of 
MRSS. Line graphs showing changes in 
individual patients over time are shown 
in Supplemental Figure 1.
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decline in myofibroblast infiltration of the deep dermis (Figure 7, 
A–C). All study patients showed a decrease in myofibroblast infil-
tration at week 3 or 4 after treatment with fresolimumab (Figure 
7D, P = 0.022). The degree of myofibroblast infiltration changed 
more consistently in patients receiving the higher dose of fresoli-
mumab (second treatment group; data not shown).
Sections were also stained for the SERPINE1 gene product, 
plasminogen activator protein-1 (PAI-1). PAI-1 has long been rec-
ognized as a target of TGF-β (27). We show above that SERPINE1 
mRNA is highly upregulated in SSc skin and its levels are reduced 
after fresolimumab treatment. PAI-1 protein staining was also 
reduced in SSc skin (Supplemental Figure 5A). Additionally, we 
examined dermal thickness in sections from patients after stain-
ing with trichrome. However, skin thickness was not found to 
change after fresolimumab treatment. (Supplemental Figure 5B).
Baseline expression of TGF-β–regulated genes predicts response to 
fresolimumab. In order to understand whether expression of some 
genes might predict patient response to fresolimumab, we exam-
ined the relationship between microarray gene expression at base-
line to the change in expression of THBS1 at week 3 or 4 and week 
7 compared with baseline. A negative correlation would indicate 
genes whose level of expression at baseline predicts a decrease in 
THBS1 expression after fresolimumab treatment.
Clustering only genes showing correlations r < –0.6 revealed 
two known TGF-β–regulated genes, ADAM metallopeptidase 
domain 12 (ADAM12) and fibronectin (FN), clustering adjacent 
to each other (r = –0.7 for both, Figure 
8A). THBS1 also clustered with these 
genes, correlating almost as highly as 
ADAM12 and FN (r = –0.67). Patients 
stratified dichotomously on the basis 
of having higher than median base-
line ADAM12 expression were found 
to significantly and more frequently 
respond to fresolimumab (decreased 
THBS1 expression compared with 
baseline; Figure 8B, P < 0.05).
We also examined whether 
expression of genes might predict the 
observed change in the MRSS. Baseline 
THBS1 expression robustly correlated 
with the change in MRSS at week 3 or 
4 and week 7 compared with that at 
baseline (r = –0.38). Patients stratified 
dichotomously on the basis of hav-
ing a higher median baseline THBS1 
expression were found to respond 
more frequently to fresolimumab, 
both biochemically (decreased THBS1 
expression compared with baseline, 
P < 0.05, data not shown) and clini-
cally (decreased MRSS compared with 
baseline, P < 0.05, Figure 8C).
Safety outcomes. The most sig-
nificant adverse events were several 
bleeding episodes and the common 
occurrence of anemia (Table 4). Two 
patients developed clinically significant gastrointestinal bleed-
ing from gastric antral vascular ectasia (GAVE); one patient 
(GC08) with a history of GAVE required hospitalization, and 
both required transfusion. Both lesions were treated effectively 
with argon laser photocoagulation. Gingival bleeding and/or 
epistaxis were described by 3 patients, and 2 patients showed 
subconjunctival hemorrhages. Hemoglobin levels decreased 
Table 3. Repeated-measures model results
WeekA β Se (β) P value
THBS1 3/4 –1.8 1.5 0.2459
7 –3.4 1.3 0.0184
24 –1.5 2.1 0.4941
COMP 3/4 –6 3.9 0.1503
7 –3.6 2.3 0.1353
24 –3.1 3.4 0.3832
MRSS 3/4 –5.1 1.1 0.0004
7 –6.3 1.6 0.002
11 –8 1.6 0.0002
17 –7.5 1.7 0.0006
24 –3.2 2.2 0.1744
ACompared with Baseline, controlling for dosing group. β, β coefficients; Se 
(β), standard error of β.
Table 2. Summary statistics on all available data (dosing groups combined)
n Mean Median SD CI (95%) P valueA
THBS1 Baseline 15 10.3 8 6.9 6.8–13.8
Week 3 14 8.4 6.2 6.3 5.1–11.7
Week 7 14 6.6 4.9 3.5 4.8–8.4
Week 24 10 6.8 5 4.5 4.0–9.6
 Change Week 3 14 –2 –1.5 5.6 –4.9–0.9 0.01353
Week 7 14 –3.2 –1 4.8 –5.7 – –0.7 0.004
Week 24 10 –1.1 –2.7 5.7 –4.6–2.4 0.5566
COMP Baseline 15 27.8 22.6 18.4 18.5–37.1
Week 3 14 21.7 13.5 18.7 11.9–31.5
Week 7 14 22.7 16.9 16.8 13.9–31.5
Week 24 10 18.6 14.2 11.2 11.7–25.5
 Change Week 3 14 –6.7 –7.9 14.8 –14.4–1.0 0.058
Week 7 14 –3.5 –4.3 8.5 –7.9–0.9 0.1531
Week 24 10 –2.9 –5.3 11.5 –10.0–4.2 0.4316
MRSS Baseline 15 26.9 24 8.6 22.5–31.2
Week 3 14 21 19 8.5 16.5–25.4
Week 7 14 20.6 18.5 9.2 15.8–25.4
Week 11 14 19.1 16.5 9.8 14.0–24.2
Week 17 12 18.3 13.5 11.2 12.0–24.6
Week 24 12 21.6 17.5 12.6 14.5–28.7
 Change Week 3 14 –5.6 –6 3.8 –7.6 – –3.6 0.0002
Week 7 14 –6.4 –5 6.4 –9.7 – –3.0 0.0032
Week 11 14 –7.9 –6 6.1 –11.1 – –4.7 0.0005
Week 17 12 –8.1 –9.5 6 –11.5 – –4.7 0.0024
Week 24 12 –4.8 –5 7.2 –8.9 – –0.7 0.0508
AWilcoxon signed-rank test on change from baseline.
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by more than 10% at some point in the trial in 10 of 15 (66.7%) 
patients (Table 4 and Supplemental Figure 6), in most cases 
resolving without further treatment. Most anemic patients had 
iron studies consistent with anemia of chronic disease, although 
several also appeared iron deficient.
One patient (GC13) with severe skin disease, who experi-
enced rapid improvement in skin sclerosis (MRSS = 37 at baseline, 
improving to 30 at 3 weeks) after receiving one dose of fresoli-
mumab (5 mg/kg), subsequently developed recurrent skin dis-
ease (MRSS = 35 at week 11) and developed shortness of breath 12 
weeks after fresolimumab dosing. This patient was subsequently 
diagnosed with severe congestive heart failure and died of heart 
failure 10 days later. A premorbid cardiac biopsy of this patient 
showed severe cardiac fibrosis, a known complication of SSc (28).
In another patient, one premalignant lesion was identified, a 
low-grade squamous intraepithelial cervical lesion found on rou-
tine PAP smear 17 weeks after fresolimumab dosing; subsequent 
colposcopy showed mild dysplasia. This patient had a history of 
abnormal PAP smears, a low-grade squamous intraepithelial 
lesion, and a positive test for HPV DNA. Subsequent to the abnor-
mal study PAP smear, the patient has had 2 normal PAP smears.
Discussion
Based on extensive in vitro and animal data, TGF-β has long been 
suspected as an important mediator of fibrosis in SSc as well as 
a variety of other fibrotic diseases, including renal, pulmonary, 
cardiac, and liver fibrosis (29–31). However, to our knowledge 
there has never previously been clinical data directly support-
ing its role in humans. Our data show that fresolimumab leads 
to a rapid decrease of TGF-β–regulated biomarker genes. For the 
predetermined primary efficacy outcome measures for the trial, 
THBS1 expression in SSc skin declined significantly in both fre-
solimumab-treated groups, while COMP trended strongly toward 
decreased expression in both groups. In addition microarray anal-
yses showed that downregulation of these genes was associated 
with downregulated expression of a larger cluster of known TGF-β–
regulated genes, including NOX4 and CTGF, both implicated as 
secondary mediators of TGF-β signaling (21, 32). Several collagen 
genes were also included in this cluster, consistent with a role for 
fresolimumab on genes directly mediating fibrosis. Expression of 
all of the genes in this cluster, most with r values greater than 0.4, 
was found to correlate with the MRSS, suggesting that these genes 
are part of a cluster of TGF-β–regulated genes that appear to play a 
driving role in TGF-β–mediated skin fibrosis in SSc.
Further supporting the pivotal role of TGF-β in SSc pathogen-
esis, patients treated with fresolimumab showed a rapid, signifi-
cant decrease in MRSS, which correlated closely with the degree 
and speed of decline in the skin biomarkers. Thus, the biomarker 
data strongly reinforce the clinical data, while robustly supple-
menting it as an objective measure. The rate of decline of the skin 
score in these patients is unprecedented in clinical trials of even 
much longer duration (18). The natural history of patients with 
early, diffuse SSc, extracting from 7 large, placebo-controlled, 
negative large trials (n = 429), showed median MRSS improve-
ments (decreases in MRSS) of 2.9 and 3.4 at 6 and 12 months (13). 
Thus, much larger and more rapid decreases in MRSS were seen 
in fresolimumab-treated patients (decreases of 5.1, 6.3, and 8 at 
week 3 or 4, 7, and 11, respectively).
TGF-β is also known to induce myofibroblasts (25), and the 
intensity of myofibroblast staining correlates highly with the 
degree of skin disease (26). Thus, decreased staining of myofi-
broblasts after fresolimumab treatment further supports the role 
of TGF-β in SSc pathogenesis as well as the observed clinical effect 
on skin disease. Expression of genes known to be highly regulated 
by TGF-β, CTGF and SERPINE (which encodes PAI-1), was also 
lower in patient skin samples 3 or 4 weeks after fresolimumab 
treatment, strongly supporting the role of TGF-β in pathogenesis 
and expression of these genes. On the other hand, skin thickness 
did not change significantly after fresolimumab treatment. The 
MRSS is primarily designed to detect changes in skin thickness; 
however, the effect of fresolimumab on the MRSS is likely due 
to changes in skin tightness and tethering that result from block-
Figure 4. Hierarchical clustering of skin gene expression in study patients. The gene cluster, including both primary outcome measures, THBS1 and 
COMP, is shown. Samples from each study patient (n = 15) are shown as columns of gene expression (red, high gene expression; green, low gene expres-
sion; black, intermediate gene expression), labeled by study visit, starting with the baseline biopsy, followed sequentially by subsequent biopsies (top of 
figure), with a blank column between each patient. Gene names and the correlation between each gene and the MRSS are shown to the right and far right, 
respectively. GalNAc-T1, UDP-N-acetyl-α-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 1. 
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two genes in the 2GSSc skin biomarker (24). The change in macro-
phage marker genes was less dramatic (and not statistically signifi-
cant in this small trial) but might suggest that TGF-β also contrib-
utes to the perivascular inflammation seen in this disease. Indeed, 
TGF-β is known to induce monocyte chemotaxis, in addition to 
its antiinflammatory properties (33), and induces Th2, Th17, and 
plasmacytoid dendritic cell migration into the skin of mice with 
mutations found in patients with stiff skin syndrome that mimic 
dermal fibrosis of SSc (34).
We found that baseline expression of THBS1 and ADAM12 
was a predictive biomarker for improved THBS1 expression after 
fresolimumab treatment and baseline THBS1 expression was pre-
dictive of improvement in the MRSS after fresolimumab treat-
ment. These observations suggest that patients might be strati-
fied for their likely response to TGF-β inhibition on the basis of 
their pretreatment gene expression. Both THBS1 and ADAM12 
are known to be induced by TGF-β (35, 36). THBS1 can also acti-
vate TGF-β, while ADAM12 has also been shown to contribute to 
ing TGF-β. These clinical manifestations of skin tightness and 
tethering might be due more to the presence of myofibroblasts 
in SSc skin and to loss of subcutaneous fat, respectively, than to 
increased skin thickness. Our data show that at least one of these 
features, myofibroblast number, changes more rapidly than skin 
thickness after TGF-β inhibition.
Notably, the statistically significant improvements in both 
clinical score and biomarker expression observed early after fre-
solimumab treatment were lost by the last study visit (week 24), 
7 or 8 drug half-lives after the last dose given in the first and sec-
ond patient groups, respectively. Thus, these data further support 
the role of fresolimumab in the observed declines in MRSS and 
biomarker gene expression and indicate a need for longer treat-
ment in future studies. Collectively, these observations strongly 
support a key role for TGF-β in SSc pathogenesis.
Patients treated with fresolimumab showed a trend of 
decreased levels of the macrophage/monocyte-associated genes, 
CD163 and MS4A4A. The latter of these genes is the second of 
Figure 5. Changes in gene expression before and 
after fresolimumab treatment. Skin biopsy RNAs 
were analyzed for expression of TGF-β–regulated 
genes, (A) CTGF, (B) SERPINE1, (C) and COL10A1, and 
a macrophage marker, (D) CD163, at baseline and 
after fresolimumab treatment. Levels from 5 healthy 
controls skin samples are also shown. CTGF, SER-
PINE1, and COL10A1 mRNA expression was assayed by 
RT-PCR; CD163 expression was assayed by NanoString. 
Statistical significance was assessed by Wilcoxon 
signed-rank. Error bars indicate SEM.
Figure 6. Decreased 2GSSc biomarker level 
in skin after fresolimumab treatment. Skin 
RNAs from patients entered into (A) the fre-
solimumab trial or (B) a clinical trial of nilotinib 
were assayed by NanoString for 2GSSc skin 
biomarker levels in baseline, week 3 or 4, and 
week 7 (fresolimumab) or at baseline and 6 
and 12 months (nilotinib). Statistical signifi-
cance was assessed by Wilcoxon signed-rank. 
Error bars indicate SEM.
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seen in patients receiving higher doses of medication. All but one 
of these patients was ultimately diagnosed pathologically as hav-
ing keratoacanthomas, and the lesions resolved spontaneously 
after fresolimumab treatment was complete, a clinical course 
more consistent with keratoacanthoma.
We did not see keratoacanthomas in our study; however, sev-
eral patients had epistaxis, gum bleeding, or subconjunctival eye 
hemorrhage, as reported in other studies of fresolimumab (46, 47). 
Although the incidence of GAVE in this study group was similar to 
that expected in such a patient cohort, the timing and severity of 
these and other bleeding incidences in our study patients dictates 
careful observation of this complication in future trials. Anemia 
in the study patients has not been reported in past trials and may 
be related to bleeding, SSc, and/or its treatment. Iron studies did 
not clearly distinguish iron deficiency from anemia of chronic 
disease (or both) in most patients. No patients showed evidence 
of hemolysis, and most showed an inappropriate response to the 
anemia (low or normal reticulocyte counts). Most patients were 
also on proton pump inhibitors, known to block iron absorption, 
and severe anemia associated with GAVE, though not correcting 
with oral iron, responded promptly to intravenous iron, consistent 
with underlying iron deficiency and preexisting gastrointestinal 
blood loss. Thus, future studies of fresolimumab in patients with 
SSc should include careful baseline evaluation for indolent gastro-
intestinal bleeding and iron deficiency.
Despite recent studies clarifying the natural history of diffuse 
cutaneous SSc as a disease that frequently remits spontaneously, 
the disease often progresses relentlessly and is associated with 
considerable mortality through a variety of complications (48). 
Although patients do not typically die directly of skin disease, 
the underlying pathogenesis for fibrotic complications, including 
fatal complications of the lung and bowel, is likely similar. Thus, 
these complications may also be driven by TGF-β and potentially 
amenable to inhibition by fresolimumab. Fresolimumab has been 
well tolerated in several trials (described above) at higher doses 
than those used in this study and multiple doses. The concern for 
side effects from TGF-β inhibition needs to be carefully weighed 
TGF-β signaling through an interaction with the type II TGF-β 
receptor (37). Notably, in recent studies, ADAM12+ pericytes were 
shown to be progenitors of myofibroblasts induced after skin or 
muscle injury, and deletion of ADAM12+ cells blocked fibrosis 
(38). Thus, it is intriguing to consider a possible role for TGF-β 
in stimulating ADAM12+ pericytes in the generation of myofibro-
blasts and fibrosis in SSc skin.
An earlier study of the TGF-β mAb CAT-192 in SSc failed to 
show any difference in change in MRSS between treatment groups 
(39). Importantly, CAT-192 targets only TGF-β1 (40), with a dis-
sociation constant of 150 nM, whereas fresolimumab is a much 
higher-affinity antibody for TGF-β1 but also targets TGF-β2 and 
TGF-β3, with dissociation constants of 2.3 nM, 2.8 nM, and 1.4 nM, 
respectively (Genzyme, unpublished Biacore analyses). Thus, the 
neutralizing activity against TGF-β2 and TGF-β3 or much higher 
target affinity may be critical in the activity of fresolimumab in SSc.
The anti–TGF-β antibody fresolimumab (also known as 
GC1008) has been tried previously in patients for several diseases. 
In patients with focal segmental glomerulosclerosis (FSGS), fre-
solimumab treatment was associated with a decline in proteinuria 
in some patients, suggesting possible efficacy in this disease, for 
which TGF-β is also strongly implicated in pathogenesis (41, 42). 
Like in SSc, THBS1 is overexpressed in FSGS renal glomeruli (43, 
44), suggesting that it may provide a strong biomarker in other 
TGF-β–mediated diseases.
Patients with malignant mesothelioma (n = 13) were treated 
with 3 mg/kg fresolimumab for up to 6 doses, showing little clini-
cal effect but also few adverse effects. One patient developed ery-
thematous, verrucous papules on biopsy, showing atypical kera-
tinocyte proliferation (45). In patients with malignant melanoma 
(n = 28) or renal cell carcinoma (n = 1), patients received up to 4 
doses of 15 mg/kg fresolimumab over a period of 56 days, with 5 
patients also receiving an additional 4 doses ranging from 0.1 to 
1 mg/kg (46). Minor bleeding (epistaxis and gingival bleeding) 
was seen frequently in these patients. In addition, several patients 
developed epithelial lesions suggestive of squamous cell carci-
noma, rather than keratoacanthoma, which is more commonly 
Figure 7. Myofibroblast infiltration in 
fresolimumab-treated patients. Sequen-
tial biopsies from patient GC17 are shown, 
comparing (B) week 4 and (C) week 7 to (A) 
baseline myofibroblast infiltration (orig-
inal magnification, ×10). Arrows indicate 
myofibroblasts. Insets show myofibroblast 
staining in the deep dermis (original mag-
nification, ×40). (D) Skin biopsies stained 
for smooth muscle actin (SMA) were 
scored by an observer blinded to biopsy 
sample for intensity of myofibroblast infil-
tration. Median values for each time point 
are shown by the red line with rectangular 
symbols (*P < 0.01, comparing week 4 to 
baseline, Wilcoxon ranked-sum).
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study was conducted after FDA review under Investigational New Drug 
110704. A Data and Safety Monitoring Board, composed of two physi-
cians external to the study investigators, reviewed all adverse events. 
Patients ≥18 years of age were included who had SSc (49) with diffuse 
cutaneous disease (50), a MRSS ≥15, and early disease, as defined by 
occurrence of the first non-Raynaud’s disease symptom within 2 years 
study entry. Patients with substantial pulmonary compromise (forced 
vital capacity less than 80% predicted, diffusion capacity less than 
70% predicted, or >20% fibrosis on computerized chest tomography); 
recent (within 6 months of study entry) scleroderma renal crisis or ele-
vated creatinine >2.0; significant arrhythmia, unstable angina, or clini-
cal heart failure; elevated liver function tests >2.5 times normal; bowel 
obstruction requiring hospitalization within 3 months or malabsorption 
requiring parenteral nutrition; recent bleeding, anemia (Hgb <8.5), or 
thrombocytopenia (platelet count <100,000/mm3); active infection; 
or any history of malignancy or history of premalignancy within 5 years 
against the prognosis of SSc and currently available therapeutics. 
Cyclophosphamide and immunoablation with stem cell transplant 
are both associated with neoplastic complications, and stem cell 
transplant is associated with considerable transplant-associated 
mortality (8). Fresolimumab is potentially a safer alternative. 
These complications, as well as the wide array of other diseases 
associated with organ fibrosis, may also be driven by TGF-β and 
respond to fresolimumab. Thus, fresolimumab holds promise as a 
potent antifibrotic therapeutic, which needs further study for the 
safety of longer-term use and for treatment of skin, lung, and gas-
trointestinal tract fibrosis.
Methods
Patients. This single-center study was approved by the Boston University 
Medical Campus Institutional Review Board and registered with clini-
caltrials.gov identifier NCT01284322 prior to patient recruitment. The 
Figure 8. THBS1 and ADAM12 expression predicts response to fresolimumab. (A) 58 genes showing correlations with the change in THBS1 expression 
at week 3 or 4 and week 7 compared with baseline of less than –0.6 were clustered. Baseline ADAM12, THBS1, and FN cluster together, showing strongly 
negative correlations with the change in THBS1 expression after fresolimumab treatment at week 3 or 4 and week 7 (red, higher expression; green, lower 
expression). Pearson correlations are shown to the right. (B) Patients were stratified into high (n = 14) and low (n = 14) baseline ADAM12 expression groups, 
based on whether they exhibited greater or less than the median level of ADAM12 expression on microarray. Patients were then graphed according to 
week 3 or 4 and week 7 THBS1 expression, compared with baseline (change in THBS1). Patient samples showing high baseline ADAM12 expression showed 
greater decreases in THBS1 after fresolimumab than patient samples with low baseline ADAM12 expression (P < 0.05, Fisher’s exact test). (C) Patient sam-
ples were stratified into high (n = 14) and low (n = 14) baseline THBS1 expression groups, based on whether they exhibited greater or less than median level 
of THBS1 expression on microarray. Samples were then graphed according to week 3 or 4 and week 7 THBS1 expression, compared with baseline (change in 
THBS1). Samples showing high baseline THBS1 expression showed greater decreases in MRSS after fresolimumab than samples with low baseline THBS1 
expression (P < 0.05, Fisher’s exact test).
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24, with skin biopsies performed again at week 
7 and, optionally, if the patient was willing, 
at week 24 at sites approximately 5 mm from 
but immediately adjacent to the most recent 
biopsy. The MRSS was assessed at each study 
visit by the same study physician. The sclero-
derma-modified health assessment question-
naire was administered at weeks 0, 7, and 24.
Safety assessments. Safety was assessed at 
each study visit using Common Terminology 
Criteria for Adverse Events v4.0. Based on 
FDA protocol recommendations, all adverse 
events were considered related to the study 
drug unless there was a clear and identifiable 
reason or explanation to reject casual relation. 
Due to concerns regarding possible promo-
tion of tumor progression by blocking TGF-β, 
in addition to routine physical exam, patients 
were monitored by complete skin, orophar-
yngeal, and nasal exams; for the second 
cohort, patients were monitored by urinalysis 
for hematuria at baseline and all subsequent 
study visits. A complete blood count with dif-
ferential and an extended metabolic panel, 
including electrolytes and liver and renal func-
tion tests, were performed at each study visit.
Skin biomarker measurements. RNA was 
collected from skin samples and placed 
directly at the bedside into RNAlater. The 
skin was minced and homogenized with a 
Polytron homogenizer, RNA was purified using the RNeasy Mini Kit 
(Qiagen), and the concentration of total RNA was measured (Nan-
odrop 1000; ThermoScientific). 200 ng of RNA was used to make 
cDNA, according to the SuperScript II RT (Invitrogen) protocol using 
random primers, and tested for THBS1, COMP, CTGF, SERPINE1, and 
COL10A1 levels by RT-PCR, normalizing values to 18S RNA and then 
normalizing the fold change to the average expression of RNAs from 
5 healthy control skin samples. Primers were purchased from Applied 
Biosystems: THBS1 (Hs00962908_m1); COMP (Hs00164359_M1); 
CTGF (Hs01026927_g1); SERPINE1 (Hs01126606_m1); and COL10A1 
(Hs0016657_m1). RNA was also analyzed by microarray on Affyme-
trix U133A2.0 microarray chips, and data were normalized using the 
MAS 5.0 algorithm. Gene expression values were clustered using Clus-
ter 2.0 (51). After filtering for genes showing differences of greater 
than 200 across all samples, genes were mean centered, normalized, 
clustered by complete linkage, and visualized using Java Treeview. 
Further exploratory analyses for inflammatory genes were carried out 
by clustering only genes selected on the basis of an expression cor-
relating with the MRSS >0.4.
RNA from skin biopsies was prepared and analyzed by microar-
ray on Affymetrix U133A2.0 microarray chips. After filtering for genes 
showing differences of greater than 200 across all samples, genes 
were mean centered, normalized, clustered by complete linkage using 
Cluster 2.0 (51), and visualized using Java Treeview. All microarray 
data have been deposited in the GEO database (accession GSE55036).
Immunohistochemical staining was carried out on formalin-
fixed, paraffin-embedded sections. For antigen retrieval, slides were 
were excluded. Patients were required to be on a stable dose of 10 mg 
per day or less of prednisone and no other immunosuppressive medica-
tion. None of the patients received any immunosuppressive medications 
before the primary outcome measures, the biomarker skin biopsies, 
were performed at week 3 or 4 and week 7. Five patients were started 
on immunosuppressive therapy during the safety follow-up. GC02 was 
started on methotrexate at week 11, which was discontinued, and the 
patient started on cyclophosphamide at week 17. GC03 was started on 
mycophenolate on week 15 after study withdrawal at the week 4 visit. 
GC11 and GC12 were started on methotrexate at week 11. GC13 was 
started on methotrexate on week 9.
Study design. Patients meeting inclusion criteria at the screen-
ing visit returned to the Boston University Medical Campus General 
Clinical Research Unit within 4 weeks. After an interim history and 
physical examination, two 3-mm skin biopsies were performed on the 
dorsal surface of the mid-forearm: one biopsy was immediately placed 
into 10% buffered formalin, and the other was placed into RNAlater 
(Qiagen). Study medication was then administered by intravenous 
infusion. The first cohort, receiving 1 mg/kg fresolimumab, returned 
after 3 weeks for safety laboratory tests and repeat skin biopsies at sites 
approximately 5 mm from but immediately adjacent to the initial biop-
sies, followed by a repeat 1 mg/kg dose of fresolimumab at week 4. Fre-
solimumab was supplied by Genzyme under Investigational New Drug 
110704, granted to the Principal Study Investigator, Robert Lafyatis. 
The second cohort, receiving a single dose of 5 mg/kg fresolimumab, 
returned at week 4 for safety laboratory tests and skin biopsies. Both 
cohorts returned for follow-up safety monitoring at weeks 7, 11, 17, and 
Table 4. Possible/probable drug-related adverse events in study patients
Adverse event Combined n (%) No. of subjects (wk from baseline visit  
to first occurrence of adverse event)
Group 1, n = 7 Group 2, n = 8
AnemiaA 10 (66.7) 5 (3, 7, 7, 7, and 17) 5 (3, 7, 7, 7, and 24)
 ReticulocytosisB 1 (6.7) 1 (7)
 ACDC 6 (26.7) 1 5
Heme-positive stool 2 (13.3) 1 (7) 1 (7)
Gastrointestinal bleedingD 2 (6.7) 1 (7) 1 (8)
EpistaxisE 2 (13.3) 1 (7) 1 (3)
Gingival bleedF 2 (13.3) 1 (3) 1 (7)
Bloodshot eye 1 (6.7) 1 (3)
Subconjunctival eye hemorrhageG 2 (13.3) 2 (10,17)
Face swelling 1 (6.7) 1 (0)
Abnormal PAP smear 1 (6.7) 1 (17)
Polyarthralgia/tendonitisD 1 (6.7) 1 (3)
Emesis 1 (6.7) 1 (7)
IV site allergic reaction 1 (6.7) 1 (7)
Headache 1 (6.7) 1 (3)  
AAnemia was defined as a decrease in hemoglobin of >10% of the screening level. BReticulocytosis 
was defined as reticulocyte percentages of >2.6%. CAnemia of chronic disease (ACD) was defined 
as subjects having both low iron and low total iron-binding capacity; at least one of these patients 
had superimposed iron deficiency (see Supplemental Figure 1). DOne episode of GI bleeding and 
the episode of polyarthralgia were categorized as severe adverse events, as each required hospital 
admission. EBoth subjects with epistaxis had prior history of epistaxis. FOne patient had prior history 
of gingival bleeding. GOne event was witnessed by the Principal Investigator, while the other event 
was self-reported by patient.
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with baseline were calculated. Changes in expression from base-
line to week 3 or 4 and week 7 were treated as independent values 
for these analyses. Genes showing correlations with fresolimumab- 
associated change in THBS1 expression of r < –0.4 or r < –0.6 were 
selected for clustering. Using Cluster 2.0, genes were mean centered, 
normalized, clustered by complete linkage, and visualized using Java 
Treeview. Fisher’s exact test was used to calculate statistical signifi-
cance on a contingency table, based on patients having higher or lower 
than median baseline ADAM12 expression and having increased or 
decreased THBS1 gene expression from baseline.
Study approval. The study was reviewed and approved by the Bos-
ton University Medical Campus Institutional Review Board, Boston, 
Massachusetts, USA. All subjects provided informed consent prior to 
their participation in the study.
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incubated in citrate buffer pH 6.1 (Dako North America) for 20 min-
utes at 90°C. Sections were then incubated with a rabbit anti–PAI-1 
(NBP2-13298, Novus Biologicals; 1:25 dilution) or mouse anti-SMA 
(clone 1A4, M0851, Dako; 1:400 dilution). After washing, the sec-
tions were incubated with polymer/HRP solution (K5361, Dako) and 
developed using DAB. Staining intensity was assessed by an observer 
blinded to the patient and visit, as described previously (26). Collagen 
thickness on trichrome-stained slides was measured using a Nikon 
Eclipse E400 microscope and SPOT Software Advanced version 4.5. 
Measurements were taken on each biopsy from the dermal epidermal 
junction to the point at which collagen staining disappeared.
Statistics. Summary statistics, including the mean, median, stan-
dard deviation, and 95% confidence limits, are reported overall and 
by dosing group for THBS1, COMP, and MRSSs at each time point and 
for change from baseline to each follow-up time point. The Wilcoxon 
signed-rank test was used to assess statistically significant changes 
in each outcome for all available data for both dosing groups, com-
bined and separately, and graphed using Prism software (GraphPad). 
Spearman’s correlations were calculated to examine the relationships 
between gene expression and MRSS.
For each outcome, a general linear model for correlated data was 
used to incorporate all of the data into a single model and account for 
potential correlation between repeated measurements on an individ-
ual. This approach uses all available data and is robust to “missing- 
at-random” data mechanisms. An unstructured covariance was used 
for all analyses. Each model contained terms for dosing group, categor-
ical time, and their interaction. The interaction was removed to assess 
the main effect of time. β Coefficients and corresponding standard 
errors are reported. These analyses were performed using SAS v9.3. 
The difference in immunohistochemical staining intensities and 
autoantibody titers, comparing baseline and after treatment in each 
patient, were analyzed using Wilcoxon signed-rank test. Statistical dif-
ferences in the changes in skin score in patient groups showing differ-
ent autoantibody status were compared using the Mann-Whitney test.
For predictive biomarker identification, Pearson correlations 
between expression of each gene analyzed by microarray and the 
difference in THBS1 expression at week 3 or 4 and week 7 compared 
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